Thus, the inhibition of the RP–MDM2–p53 axis might be a therapeutic avenue to consider for functional intervention, although further studies are needed to identify the upstream mechanisms leading to the p53 pathway activation observed in HLHS proband cells. The gene discussed is MDM2; the disease is hypoplastic left heart syndrome.